Ventyx Biosciences (VTYX) Stock Forecast, Price Target & Predictions
VTYX Stock Forecast
Ventyx Biosciences (VTYX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $33.86, with a high of $60.00 and a low of $6.00. This represents a 1880.12% increase from the last price of $1.71.
VTYX Stock Rating
Ventyx Biosciences stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).
Buy
VTYX Price Target Upside V Benchmarks
Type | Name | Upside |
---|---|---|
Stock | Ventyx Biosciences | 1880.12% |
Sector | Healthcare Stocks | 26.69% |
Industry | Biotech Stocks | 63.51% |
Price Target Trends
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | 4 |
Avg Price Target | - | - | $11.00 |
Last Closing Price | $1.71 | $1.71 | $1.71 |
Upside/Downside | - | - | 543.27% |
Ratings Trends
Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
---|---|---|---|---|---|---|
Feb, 25 | 1 | 5 | 3 | - | - | 9 |
Jan, 25 | 1 | 5 | 3 | - | - | 9 |
Dec, 24 | 1 | 5 | 3 | - | - | 9 |
Nov, 24 | 2 | 5 | 3 | - | - | 10 |
Oct, 24 | 2 | 5 | 3 | - | - | 10 |
Analyst Price Target Forecasts
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Jun 13, 2024 | Emily Bodnar | H.C. Wainwright | $6.00 | $2.98 | 101.34% | 250.88% |
Jun 06, 2024 | Jeff Jones | Oppenheimer | $10.00 | $5.28 | 89.39% | 484.80% |
Mar 12, 2024 | Derek Archila | Wells Fargo | $16.00 | $8.42 | 90.02% | 835.67% |
Mar 12, 2024 | Jeff Jones | Oppenheimer | $12.00 | $8.42 | 42.52% | 601.75% |
Dec 19, 2022 | Goldman Sachs | $50.00 | $32.64 | 53.19% | 2823.98% | |
Nov 17, 2022 | Matthew Harrison | Morgan Stanley | $45.00 | $25.43 | 76.96% | 2531.58% |
Sep 13, 2022 | Michael Yee | Jefferies | $60.00 | $38.11 | 57.44% | 3408.77% |
May 12, 2022 | Yasmeen Rahimi | Piper Sandler | $50.00 | $14.53 | 244.12% | 2823.98% |
Analyst Rating Forecasts
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jan 14, 2025 | H.C. Wainwright | Neutral | Neutral | hold |
Oct 16, 2024 | H.C. Wainwright | Neutral | Neutral | hold |
Sep 24, 2024 | H.C. Wainwright | Neutral | Neutral | hold |
Jun 13, 2024 | H.C. Wainwright | Neutral | Neutral | hold |
Jun 06, 2024 | Piper Sandler | Overweight | Overweight | hold |
Jun 06, 2024 | Oppenheimer | Outperform | Outperform | hold |
Mar 12, 2024 | Wells Fargo | Overweight | upgrade | |
Dec 19, 2022 | Goldman Sachs | Buy | initialise | |
Sep 13, 2022 | Needham | Buy | Buy | hold |
Sep 12, 2022 | Oppenheimer | Outperform | Outperform | hold |
Financial Forecast
EPS Forecast
Annual
Dec 23 | Dec 24 | Dec 25 | Dec 26 | Dec 27 | Dec 28 | |
---|---|---|---|---|---|---|
Reported | - | - | - | - | - | - |
Avg Forecast | $-3.37 | $-2.10 | $-2.06 | $-1.77 | $-1.16 | $-0.33 |
High Forecast | $-2.77 | $-2.01 | $-1.29 | $-1.09 | $3.04 | $-0.33 |
Low Forecast | $-3.77 | $-2.19 | $-3.35 | $-2.26 | $-3.93 | $-0.33 |
Surprise % | - | - | - | - | - | - |
Revenue Forecast
Annual
Dec 23 | Dec 24 | Dec 25 | Dec 26 | Dec 27 | Dec 28 | |
---|---|---|---|---|---|---|
Reported | - | - | - | - | - | - |
Avg Forecast | - | - | - | $15.28M | $124.12M | $260.19M |
High Forecast | - | - | - | $15.28M | $124.12M | $260.19M |
Low Forecast | - | - | - | $15.28M | $124.12M | $260.19M |
Surprise % | - | - | - | - | - | - |
Net Income Forecast
Annual
Dec 23 | Dec 24 | Dec 25 | Dec 26 | Dec 27 | Dec 28 | |
---|---|---|---|---|---|---|
Reported | $-192.96M | - | - | - | - | - |
Avg Forecast | $-192.96M | $-122.72M | $-174.73M | $-98.22M | $-166.72M | $-19.36M |
High Forecast | $-162.43M | $-117.44M | $-75.44M | $-63.97M | $178.13M | $-19.36M |
Low Forecast | $-220.44M | $-128.01M | $-196.02M | $-132.47M | $-229.80M | $-19.36M |
Surprise % | - | - | - | - | - | - |